The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Preliminary studies have illuminated the promising nature of ciprofol, indicating its
enhanced safety spectrum, superior potency, and a diminished likelihood of experiencing
injection-related discomfort. Venturing deeper, this research embarked on an ambitious quest
to measure the 95% effective volume of ciprofol for induction of general anesthesia by a
modified sequential method and juxtapose the 95% effective volume dosage of ciprofol against
a corresponding dose of remimazolam during the initiation of general anesthesia. The study
delved into diverse anesthetic protocols, meticulously scrutinizing the safety and efficacy
credentials of ciprofol. The ultimate vision was to pave a robust foundation for the
sophisticated and judicious utilization of ciprofol in clinical landscapes.
Phase:
Phase 4
Details
Lead Sponsor:
The Second Affiliated Hospital of Hainan Medical University